Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Low molecular weight heparin (LMWH) Clear all
Completed Not applicable Interventional

Comparison of Apixaban Versus Enoxaparin

NCT06243510
View directory record Official record
Conditions
Bladder Cancer
Interventions
apixaban, enoxaparin
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 3 Interventional

SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes

NCT00043784
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Myocardial Ischemia
Interventions
enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Oct 9, 2026, 9:25 PM EDT
Not listed No phase listed Observational

Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma

NCT06025162
View directory record Official record
Conditions
Thromboembolism, Venous
Interventions
enoxaparin
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 9, 2026, 9:25 PM EDT
Completed No phase listed Observational

A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US

NCT04141228
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
28,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Flemington, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 9, 2026, 9:25 PM EDT
Enrolling by invitation Phase 4 Interventional

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

NCT03244020
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases, Venous Thromboembolism, Hematoma, Anticoagulant-induced Bleeding
Interventions
Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2,868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial

NCT04354155
View directory record Official record
Conditions
Infection Viral, Thromboses, Venous, COVID-19
Interventions
Enoxaparin Prefilled Syringe [Lovenox]
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
0 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 9, 2026, 9:25 PM EDT
Terminated Not applicable Interventional Results available

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients

NCT00521885
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (Fondaparinox) 2.5 mg SC Daily, Lovenox 40mg SC Daily
Drug
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

NCT00585182
View directory record Official record
Conditions
Obesity, Venous Thrombosis, Anticoagulants
Interventions
Enoxaparin 0.5 mg/kg once daily
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03891524
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma

NCT03339349
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 9, 2026, 9:25 PM EDT
Terminated Not applicable Interventional Results available

Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)

NCT02887820
View directory record Official record
Conditions
Heart Disease, Lung Disease
Interventions
Thromboelastograph
Device
Lead sponsor
Stephen Esper
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 2 Interventional

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

NCT00252005
View directory record Official record
Conditions
Deep-Vein Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Albuquerque, New Mexico • Chapel Hill, North Carolina • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Not applicable Interventional Results available

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735
View directory record Official record
Conditions
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions
ActiveCare CECT device, Enoxaparin
Device · Drug
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Not applicable Interventional Results available

Once Weekly Subcutaneous Ports for the Administration of Anticoagulants

NCT00774748
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Insuflon
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

NCT00942968
View directory record Official record
Conditions
Cancer
Interventions
dalteparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
21
States / cities
Tucson, Arizona • Pleasant Hill, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Early Phase 1 Interventional

Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose

NCT02704052
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolus, Venous Thromboembolism
Interventions
Real time enoxaparin dose adjustment, Standard enoxaparin dose
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 9, 2026, 9:25 PM EDT
Terminated Phase 2 Interventional

Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

NCT01312935
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Coronary Artery Disease (CAD), Angioplasty
Interventions
PMX-60056
Drug
Lead sponsor
PolyMedix, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
South Bend, Indiana • Detroit, Michigan • Rapid City, South Dakota
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 4 Interventional Results available

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

NCT04505774
View directory record Official record
Conditions
Covid19
Interventions
theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor
Drug
Lead sponsor
Matthew Neal MD
Other
Eligibility
18 Years and older
Enrollment
3,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
81
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 3 Interventional Results available

Cancer Venous Thromboembolism (VTE)

NCT02073682
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
Interventions
Edoxaban, Dalteparin, Low molecular weight heparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 3 Interventional Results available

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

NCT01895777
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
dabigatran etexilate, standard of care
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Up to 17 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

NCT02981472
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
28 Days to 17 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 9, 2026, 9:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

NCT03000673
View directory record Official record
Conditions
Antithrombotic
Interventions
Enoxaparin, unfractionated heparin (UFH), BMS-986177
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 9, 2026, 9:25 PM EDT